Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | APEX1 | P27695 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11362739 | 0.70 | TSHR (0.59) | MAPTMEN1POLBKMT2AAPEX1 | |
| SCHEMBL5362573 | 0.68 | KDM4E (0.51) | MAPTMEN1POLBKMT2AAPEX1 | |
| SCHEMBL176271 | 0.65 | — | — | |
| SCHEMBL7553199 | 0.65 | ALDH1A1 (0.56) | MAPTPOLBL3MBTL1TSHRALDH1A1 | |
| SCHEMBL2795967 | 0.65 | ALDH1A1 (0.54) | MAPTMEN1POLBKMT2AAPEX1 | |
| SCHEMBL11699502 | 0.64 | TSHR (0.58) | MAPTMEN1POLBKMT2ATDP1 | |
| SCHEMBL2115613 | 0.64 | MAPT (1.00) | MAPTMEN1POLBKMT2AAPEX1 | |
| SCHEMBL23009248 | 0.63 | KDM4E (0.63) | MAPTMEN1POLBKMT2AAPEX1 | |
| SCHEMBL31267078 | 0.63 | TSHR (0.50) | MAPTMEN1POLBKMT2AAPEX1 | |
| SCHEMBL18462113 | 0.63 | ADORA2B (0.48) | MAPTMEN1KMT2AHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015638-A1 | Use of N-(1,3,4-Oxadiazol-2-yl)arylcarboxamides or their salts for controlling unwanted plants in areas of transgenic crop plants being tolerant to HPPD inhibitor herbicides | BASF SE (DE) | 2017-01-19 | — | — | US | disclosed |
| US-9101141-B2 | N-(1,3,4-oxadiazol-2-yl)arylcarboxamides and use thereof as herbicides | BAYER INTERLLECTUAL PROPERTY GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-20140080705-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES AND USE THEREOF AS HERBICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015638-A1 | Use of N-(1,3,4-Oxadiazol-2-yl)arylcarboxamides or their salts for controlling unwanted plants in areas of transgenic crop plants being tolerant to HPPD inhibitor herbicides | HPD, AADAC, PGD | MAPT 4442/4885MEN1 4807/4885POLB 360/4885 |
| US-20140080705-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES AND USE THEREOF AS HERBICIDES | PRDX4, CBR3, AOX1 | MAPT 4744/4885MEN1 4775/4885POLB 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.